CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · IEX Real-Time Price · USD
1.320
-0.010 (-0.75%)
At close: Jul 2, 2024, 4:00 PM
1.260
-0.060 (-4.55%)
After-hours: Jul 2, 2024, 7:39 PM EDT
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CytomX Therapeutics stock have an average target of 5.77, with a low estimate of 3.50 and a high estimate of 8.00. The average target predicts an increase of 337.12% from the current stock price of 1.32.
Analyst Consensus: Buy
* Price targets were last updated on May 28, 2024.
Analyst Ratings
The average analyst rating for CTMX stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 3 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 27, 2024 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $2.25 → $3.5 | Hold → Buy | Upgrades | $2.25 → $3.5 | +165.15% | May 28, 2024 |
| BMO Capital | BMO Capital | Hold Maintains $3.25 → $3.59 | Hold | Maintains | $3.25 → $3.59 | +171.97% | May 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 9, 2024 |
| Wedbush | Wedbush | Hold → Buy Upgrades $3 → $8 | Hold → Buy | Upgrades | $3 → $8 | +506.06% | May 9, 2024 |
Financial Forecast
Revenue This Year
104.93M
from 101.21M
Increased by 3.67%
Revenue Next Year
78.09M
from 104.93M
Decreased by -25.58%
EPS This Year
-0.35
from -0.01
EPS Next Year
-0.56
from -0.35
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 160.1M | 106.1M | 88.9M | 93.7M | 148.3M |
| Avg | 104.9M | 78.1M | 45.8M | 47.3M | 105.7M |
| Low | 77.4M | 35.3M | n/a | n/a | 49.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 58.2% | 1.1% | 13.9% | 104.5% | 213.3% |
| Avg | 3.7% | -25.6% | -41.4% | 3.3% | 123.4% |
| Low | -23.5% | -66.4% | - | - | 3.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.16 | -0.29 | -0.63 | -1.17 | -0.08 |
| Avg | -0.35 | -0.56 | -0.90 | -1.13 | -0.08 |
| Low | -0.53 | -0.94 | -1.12 | -1.09 | -0.08 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.